menu
    • menu
    [{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sosei Heptares","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Sosei Heptares \/ Formosa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Heptares \/ Formosa Pharmaceuticals"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"PLA2","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"PLA2","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Eyenovia \/ William Blair","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ William Blair"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Crist\u00e1lia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Crist\u00e1lia","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ Crist\u00e1lia"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Sosei Group Corporation \/ Formosa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Formosa Pharmaceuticals"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"NovaBay Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":"14","companyTruncated":"Formosa Pharmaceuticals \/ Apotex Inc"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Alliance Global Partners","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Alliance Global Partners"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"14","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":null,"graph2":null,"graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eyenovia \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Clobetasol

    Menu

    Clobetasol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Alliance Global Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

                            Details : The Company intends to use the net proceeds to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 27, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Alliance Global Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Launches Clobetasol Propionate Suspension for Post-Ocular Surgery Pain

                            Details : APP13007 (clobetasol propionate) ophthalmic suspension 0.05% is approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Dawson James Securities

                            Deal Size : $5.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Eyenovia Announces Closing of Public Offering

                            Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 23, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Dawson James Securities

                            Deal Size : $5.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Dawson James Securities

                            Deal Size : $5.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Eyenovia Announces Pricing of $5.14 Million Public Offering

                            Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 21, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Dawson James Securities

                            Deal Size : $5.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Dawson James Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Eyenovia, Inc. Announces Proposed Public Offering

                            Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 20, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Dawson James Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Eyenovia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Formosa and Eyenovia Begin Co-Development of Clobetasol for Acute Dry Eye Disease

                            Details : APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of dry eye disease.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 07, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Eyenovia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa Pharmaceuticals Announce Licensing Agreement with Apotex for Clobetasol Propionate

                            Details : Through the licensing agreement, Apotex will gain exclusive rights of APP13007 (clobetasol propionatei) in Canada for commercialization to treat inflammation and pain following ocular surgery.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Tabuk Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk for Clobetasol

                            Details : Tabuk gains rights to APP13007 (clobetasol propionate) for post-ocular surgery pain and inflammation in the MENA region.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 09, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Tabuk Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Eyenovia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NovaBay and Eyenovia to Co-Promote Ophthalmic Products to U.S. Eyecare Pros

                            Details : NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension, a steroid for inflammation and pain after ocular surgery, via U.S. physician-dispensed channels.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 13, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Eyenovia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sosei Group Corporation

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals

                            Details : APP13007 (clobetasol propionate) is a nanoparticle steroid formulation for treating inflammation and pain post-cataract surgery, with milestone payments to Sosei Heptares based on pipeline progress.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 06, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth